What is the 13F Pro Quality Score for ARCT?

13F Pro ranks Arcturus Therapeutics Holdings Inc. (ARCT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ARCT's current score at https://13fpro.ai/research/ARCT (free sign-up required for the full ranking).

Which hedge funds own the most ARCT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ARCT include FEDERATED HERMES,, ARK Investment Management, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ARCT as soon as new 13F filings post.

Where does 13F Pro source ARCT data?

All Arcturus Therapeutics Holdings Inc. fundamentals and ownership data come directly from SEC EDGAR. Arcturus Therapeutics Holdings Inc. files with the SEC under CIK 1768224. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ARCT in?

Arcturus Therapeutics Holdings Inc. (ARCT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ARCT research updated on 13F Pro?

ARCT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Arcturus Therapeutics Holdings Inc.(ARCT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1768224 ARCT stock profile & AI dashboard →

13F Pro Quality Score

12.0/100

Rank #2,787 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

3.8/100

Profitability

7.8/100

Balance Sheet

10.2/100

Earnings Quality

30.0/100

Free Cash Flow

6.8/100

Institutional Flow

62.9/100

Revenue Scale

14.7/100

Dilution Risk

6.3/100

ARCT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Arcturus Therapeutics Holdings Inc. (ARCT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARCT at 12.0/100 on a 32-signal composite quality model, placing it at rank #2,787 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (3.8) and free cash flow (6.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Arcturus Therapeutics Holdings Inc. reports quarterly revenue of $2.1M, net income of $-27.0M, free cash flow of $-19.4M. Top institutional holders of ARCT by reported 13-F value include FEDERATED HERMES,, ARK Investment Management, BlackRock,, based on the most recent SEC filings. ARCT trades on the Nasdaq exchange and files with the SEC under CIK 1768224. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARCT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcturus Therapeutics Holdings Inc. directly from SEC EDGAR. Arcturus Therapeutics Holdings Inc.'s 13F Pro composite quality score has ranged between 6 and 41 since 2021, currently 12.0 — a stable long-term trajectory across 28 quarterly and live scoring snapshots.

✦

Fun facts about Arcturus Therapeutics Holdings Inc.

Quirks, history, and lore behind ARCT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
Revenue is modest — think tens of millions rather than billions — as the company relies heavily on partnership deals and collaboration agreements to fund its pipeline.
3
The History
Founded around 2013, it emerged from the wave of excitement around RNA medicines and staked its claim before mRNA became a household word.
4
The Secret
Its proprietary platform, LUNAR, uses lipid nanoparticle delivery to shuttle RNA therapies into cells — the same general technology that later powered COVID-19 vaccines worldwide.
5
The Lore
It has partnered with CSL Behring and others to develop treatments for rare diseases, and its pipeline includes candidates targeting cystic fibrosis and liver diseases.
6
The Giveaway
Named after a bright star in the constellation Boötes, this San Diego RNA medicines company has a ticker that sounds like it belongs in the night sky: ARCT.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$2.1M

Net Income

Q1 2026

$-27.0M

Free Cash Flow

Q1 2026

$-19.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-46.1% YoY

$82.0MFY 2025

FY22 $206.0MFY23 $166.8MFY24 $152.3MFY25 $82.0M

Net Income

+18.7% YoY

$-65.8MFY 2025

FY22 $9.3MFY23 $-29.7MFY24 $-80.9MFY25 $-65.8M

Operating Income

+20.3% YoY

$-76.3MFY 2025

FY22 $12.2MFY23 $-78.2MFY24 $-95.7MFY25 $-76.3M

EPS (Diluted)

+20.0% YoY

$-2.40FY 2025

FY22 $0.35FY23 $-1.12FY24 $-3.00FY25 $-2.40

Total Assets

-21.2% YoY

$271.1MFY 2025

FY22 $450.4MFY23 $429.4MFY24 $344.1MFY25 $271.1M

Total Debt

—FY 2025

FY22 $60.7MFY23 —FY24 —FY25 —

Op. Cash Flow

-24.3% YoY

$-74.3MFY 2025

FY22 $32.0MFY23 $-18.1MFY24 $-59.7MFY25 $-74.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$82.0M -46.1%	$152.3M -8.7%	$166.8M -19.0%	$206.0M +1566.8%	$12.4M +29.6%	$9.5M
Net Income	$-65.8M +18.7%	$-80.9M -172.3%	$-29.7M -417.9%	$9.3M +104.6%	$-203.7M -182.3%	$-72.1M
Operating Income	$-76.3M +20.3%	$-95.7M -22.3%	$-78.2M -742.2%	$12.2M +106.0%	$-202.9M -183.6%	$-71.5M
EPS (Diluted)	$-2.40 +20.0%	$-3.00 -167.9%	$-1.12 -420.0%	$0.35 +104.5%	$-7.74	—
Total Assets	$271.1M -21.2%	$344.1M -19.9%	$429.4M -4.7%	$450.4M +14.7%	$392.8M -17.6%	$476.5M
Total Debt	—	—	—	$60.7M -3.9%	$63.1M +281.3%	$16.6M
Operating Cash Flow	$-74.3M -24.3%	$-59.7M -230.1%	$-18.1M -156.6%	$32.0M +123.7%	$-135.0M -215.1%	$-42.9M

AI Insight: ARCT Financial Trends

Arcturus is in severe financial distress with revenue collapsing 96% from Q2 2024 to Q1 2026 while cash burn accelerates.

• Revenue fell from $50M (Q2 2024) to $2M (Q1 2026), a 96% decline over eight quarters.

• Operating losses widened from $21M (Q2 2024) to $29M (Q1 2026) despite collapsing revenue base.

• Equity eroded from $259M to $191M over the period, reflecting sustained cumulative net losses.

⚠ Operating cash flow deteriorated to negative $19M in Q1 2026; company burning cash while unprofitable.

⚠ Q4 2025 net loss of $29M signals potential milestone event or one-time charge; context unclear from financials.

AI Insight: ARCT Ratio Trends

Arcturus remains unprofitable with deteriorating returns; Q4 2025 and Q1 2026 show sharply negative ROIC and ROA, reversing modest Q2–Q3 2025 improvement.

• ROIC worsened to −60.5% in Q1 2026 from −20.1% in Q2 2025, erasing six-month recovery and signaling renewed operational strain.

• Operating margin data unavailable Q4 2025 onward; NPM missing same periods, limiting visibility into cost structure and profitability drivers.

⚠ ROE collapsed to −56.4% in Q1 2026 versus −15.9% in Q2 2025; equity destruction accelerating despite minimal leverage (D/E 0.06).

⚠ Q4 2025 marked sharp deterioration (ROIC −58.5%, ROA −42.9%) after Q3 improvement; pattern suggests potential one-time charge or revenue cliff.

Get alerted when ARCT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Arcturus Therapeutics Holdings Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ARCT

FEDERATED HERMES, INC.
$25.5M3,303,640 sh
ARK Investment Management LLC
$21.4M2,769,518 sh
BlackRock, Inc.
$20.2M2,613,281 sh
Sumitomo Mitsui Trust Holdings, Inc.
$17.7M2,288,935 sh
Nikko Asset Management Americas, Inc.
$17.6M2,288,935 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.5M1,107,020 sh
TWO SIGMA INVESTMENTS, LP
$8.4M1,081,784 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$7.5M977,922 sh
GEODE CAPITAL MANAGEMENT, LLC
$5.1M660,928 sh
STATE STREET CORP
$4.2M543,863 sh

Fund	Value	Shares
FEDERATED HERMES, INC.	$25.5M	3,303,640
ARK Investment Management LLC	$21.4M	2,769,518
BlackRock, Inc.	$20.2M	2,613,281
Sumitomo Mitsui Trust Holdings, Inc.	$17.7M	2,288,935
Nikko Asset Management Americas, Inc.	$17.6M	2,288,935
VANGUARD CAPITAL MANAGEMENT LLC	$8.5M	1,107,020
TWO SIGMA INVESTMENTS, LP	$8.4M	1,081,784
VANGUARD PORTFOLIO MANAGEMENT LLC	$7.5M	977,922
GEODE CAPITAL MANAGEMENT, LLC	$5.1M	660,928
STATE STREET CORP	$4.2M	543,863

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ARCT on your watchlist

Track score changes the day Arcturus Therapeutics Holdings Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ARCT a good stock to buy?

13F Pro's AI-powered analysis of Arcturus Therapeutics Holdings Inc. (ARCT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARCT are available on the ARCT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ARCT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARCT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Arcturus Therapeutics Holdings Inc.'s investment landscape.